pISSN 1226-6051
eISSN 2508-786X

Table. 3.

Table. 3.

Characteristics of adverse event reports on varenicline and other drugs from 2013 to 2017

Characteristics Varenicline All other drugs p-value
Sex Male 1,222 (87.4%) 1,133,519 (42.5%) < 0.0001
Female 176 (12.6%) 1,530,512 (57.5%)

Age group 0~18 0 17,590 (8.7%) < 0.0001
19~64 406 (88.3%) 139,280 (68.6%)
65 54 (11.7%) 46,265 (22.8%)

Report type Spontaneous report 895 (64.0%) 1,592,399 (59.8%) 0.0002
Research(including review) 501 (35.8%) 1,037,299 (38.9%)
Literature 2 (0.1%) 21,932 (0.8%)
Unknown 0 10 (<0.1%)
Others 0 12,391 (0.5%)

Report source by person Clinician 623 (44.8%) 1,279,571 (49.0%) < 0.0001
Pharmacist 351 (25.2%) 383,631 (14.7%)
Nurse 226 (16.2%) 824,088 (31.6%)
Consumer 170 (12.2%) 80,816 (3.1%)
Others 21 (1.5%) 38,267 (1.5%)
Medical professional 0 3,385 (0.1%)
Lawyer 0 14 (<0.1%)

Report source by affiliation Regional pharmacovigilance center 692 (49.5%) 1,473,705 (55.3%) < 0.0001
Pharmaceutical company 647 (46.3%) 1,118,370 (42.0%)
Healthcare institutions 8 (0.6%) 49,328 (1.9%)
Pharmacy 4 (0.3%) 3,290 (0.1%)
Public health center 0 90 (<0.1%)
Consumer 46 (3.3%) 14,739 (0.6%)
Others 1 (0.1%) 4,497 (0.2%)
Korean J Clin Pharm 2022;32:1-7 https://doi.org/10.24304/kjcp.2022.32.1.1
© 2022 Korean J Clin Pharm